Davidson Michael Harvey's most recent trade in NewAmsterdam Pharma Company NV was a trade of 443,707 Ordinary Shares done at an average price of $33.3 . Disclosure was reported to the exchange on March 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 02 Mar 2026 | 443,707 | 174,144 | - | 33.3 | 14,753,258 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 443,707 | 617,851 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 443,707 | 239,267 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 183,332 | 643,191 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 183,332 | 682,974 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.63 per share. | 24 Feb 2026 | 165,408 | 477,783 | - | 33.6 | 5,562,671 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 64,708 | 524,567 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 64,708 | 924,559 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.13 per share. | 24 Feb 2026 | 61,547 | 463,020 | - | 36.1 | 2,223,693 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 58,253 | 518,112 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 58,253 | 866,306 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.11 per share. | 24 Feb 2026 | 46,517 | 471,595 | - | 35.1 | 1,633,212 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.44 per share. | 24 Feb 2026 | 17,924 | 174,144 | - | 34.4 | 617,303 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.96 per share. | 24 Feb 2026 | 10,436 | 461,159 | - | 36.0 | 375,279 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.46 per share. | 24 Feb 2026 | 3,161 | 459,859 | - | 36.5 | 115,250 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.68 per share. | 24 Feb 2026 | 1,300 | 459,859 | - | 36.7 | 47,684 | Ordinary Shares |
| Tenax Therapeutics Inc | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 364,000 | 364,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 81,000 | 459,859 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Jan 2026 | 11,582 | 378,859 | - | - | Ordinary Shares | |
| Tenax Therapeutics Inc | Michael Davidson Harvey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| BioAge Labs Inc | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 38,394 | 402,699 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 38,394 | 0 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 38,394 | 38,394 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 30,992 | 364,305 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Mar 2025 | 12,258 | 390,441 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 670,467 | 670,467 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 123,529 | 123,529 | - | - | Ordinary Shares | |
| Silence Therapeutics PLC (ADR) | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,000 | 48,000 | - | - | Share Option (Right to Buy) | |
| Tenax Therapeutics Inc | Davidson Michael Harvey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Oct 2024 | 15,000 | 85,000 | - | - | Warrant (right to buy) | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.27 per share. | 20 Aug 2024 | 5,000 | 209,784 | - | 16.3 | 81,350 | Ordinary Shares |
| Tenax Therapeutics Inc | Michael Harvey Davidson | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Aug 2024 | 47,500 | 47,500 | - | - | Pre-Funded Warrant | |
| Tenax Therapeutics Inc | Michael Harvey Davidson | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Aug 2024 | 25,000 | 25,000 | - | - | Warrant | |
| Tenax Therapeutics Inc | Michael Harvey Davidson | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 08 Aug 2024 | 2,500 | 2,881 (0%) | 0% | - | Common Stock | |
| NewAmsterdam Pharma Co NV | Michael Harvey Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.26 per share. | 20 Jun 2024 | 5,000 | 204,784 | - | 17.3 | 86,309 | Ordinary Shares |
| BioAge Labs Inc | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 33,986 | 33,986 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| NewAmsterdam Pharma Co NV | Davidson Harvey Michael | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 1,039,939 | 1,039,939 | - | - | Option (right to buy) | |
| Lisata Therapeutics Inc | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 65,430 | 209,753 (1%) | 0% | 0 | Common Stock |